NCT02588677View on ClinicalTrials.gov

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 5, 2016

Study Completion Date

March 31, 2018

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

Masitinib (4.5)

4.5 mg/kg/day

DRUG

Riluzole

DRUG

Placebo

DRUG

Masitinib (3.0)

3 mg/kg/day

Trial Locations (1)

28029

Hospital Carlos III, Madrid

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY